Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study

DADE - Dupilumab for Atopic Dermatitis of the Elderly study group

doi:10.1111/jdv.17094

Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study

DADE - Dupilumab for Atopic Dermatitis of the Elderly study group

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.

OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.

METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.

RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.

CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

Original language	English
Journal	Journal of the European Academy of Dermatology and Venereology : JEADV
DOIs	https://doi.org/10.1111/jdv.17094
Publication status	E-pub ahead of print - Dec 17 2020

Access to Document

10.1111/jdv.17094

Fingerprint Dive into the research topics of 'Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study'. Together they form a unique fingerprint.

Cite this

@article{d3e5ea8ac1d5446cbda52a79b5154b52,

title = "Dupilumab therapy of atopic dermatitis of the elderly: a multi-centre, real-life study",

abstract = "BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.",

author = "{DADE - Dupilumab for Atopic Dermatitis of the Elderly study group} and C Patruno and M Napolitano and G Argenziano and K Peris and M Ortoncelli and G Girolomoni and A Offidani and Ferrucci, {S M} and Amoruso, {G F} and M Rossi and L Stingeni and G Malara and T Grieco and C Foti and M Gattoni and C Loi and M Iannone and M Talamonti and G Stinco and F Rongioletti and Pigatto, {P D} and A Cristaudo and E Nettis and M Corazza and F Guarneri and P Amerio and M Esposito and {Belloni Fortina}, A and C Potenza and G Fabbrocini",

year = "2020",

month = dec,

day = "17",

doi = "10.1111/jdv.17094",

language = "English",

journal = "Journal of the European Academy of Dermatology and Venereology",

issn = "0926-9959",

publisher = "wiley",

}

TY - JOUR

T1 - Dupilumab therapy of atopic dermatitis of the elderly

T2 - a multi-centre, real-life study

AU - DADE - Dupilumab for Atopic Dermatitis of the Elderly study group

AU - Patruno, C

AU - Napolitano, M

AU - Argenziano, G

AU - Peris, K

AU - Ortoncelli, M

AU - Girolomoni, G

AU - Offidani, A

AU - Ferrucci, S M

AU - Amoruso, G F

AU - Rossi, M

AU - Stingeni, L

AU - Malara, G

AU - Grieco, T

AU - Foti, C

AU - Gattoni, M

AU - Loi, C

AU - Iannone, M

AU - Talamonti, M

AU - Stinco, G

AU - Rongioletti, F

AU - Pigatto, P D

AU - Cristaudo, A

AU - Nettis, E

AU - Corazza, M

AU - Guarneri, F

AU - Amerio, P

AU - Esposito, M

AU - Belloni Fortina, A

AU - Potenza, C

AU - Fabbrocini, G

PY - 2020/12/17

Y1 - 2020/12/17

N2 - BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

AB - BACKGROUND: Treatment of moderate-to-severe atopic dermatitis in the elderly may be challenging, due to side effects of traditional anti-inflammatory drugs and to comorbidities often found in this age group. Furthermore, efficacy and safety of innovative drugs such as dupilumab is not yet well known.OBJECTIVES: A multicentre retrospective, observational, real-life study on the efficacy and safety of dupilumab was conducted in a group of patients aged ≥ 65 years and affected by severe AD. Their main clinical features were also examined.METHODS: Data of elderly patients with severe (EASI≥24) AD treated with dupilumab at label dosage for 16 weeks were retrospectively collected. Treatment outcome was assessed by comparing objective (EASI) and subjective (P-NRS, S-NRS, and DLQI) scores at baseline and after 16 weeks of treatment.RESULTS: Two hundred and seventy-six patients were enrolled in the study. They represented 11.37% of all patients with severe AD. Flexural eczema was the most frequent clinical phenotype, followed by prurigo nodularis, The coexistence of more than 1 phenotype was found in 63/276 (22.82%) subjects. Data on the 16-week treatment with dupilumab were available for 253 (91.67%) patients. Efficacy of dupilumab was demonstrated by a significant reduction of all the scores. No statistically significant difference regarding efficacy was found in elderly patients when compared to the group of our AD patients aged 18-64 years, treated with dupilumab over the same period. Furthermore, only 18 (6.52%) patients discontinued the drug due to inefficacy. Sixty-one (22.51%) patients reported adverse events, conjunctivitis and flushing being the most frequent. One (0.36%) patient only discontinued dupilumab due to an adverse event.CONCLUSIONS: Therapy with dupilumab led to a significant improvement of AD over a 16-week treatment period, with a good safety profile. Therefore, dupilumab could be considered as an efficacious and safe treatment for AD also in the elderly.

U2 - 10.1111/jdv.17094

DO - 10.1111/jdv.17094

M3 - Article

C2 - 33332697

JO - Journal of the European Academy of Dermatology and Venereology

JF - Journal of the European Academy of Dermatology and Venereology

SN - 0926-9959

ER -